2020 and Beyond: How Immunotherapy is Changing the Game in Bladder Cancer Management

Please Note: Credit Is No Longer Available


It is estimated that there are >81,000 new cases of metastatic urothelial bladder cancer (mUBC) in the U.S each year, resulting in more than 17,000 bladder cancer specific deaths. For more than three decades, systemic platinum-based chemotherapy has been the standard first-line treatment for patients with inoperable or advanced metastatic bladder cancer. Fortunately, mUBC has now been shown to be susceptible to immune checkpoint inhibitors (ICIs), with these agents demonstrating recognized and well tolerated safety profiles, especially in comparison to traditional platinum-based chemotherapy. Join Drs. Neal Shore, Ashish Kamat, and Noah Hahn for this on-demand online activity, as they discuss considerations for implementing immunotherapy into your bladder cancer management clinic. 

This activity is presented by Creative Educational Concepts and Bladder Cancer Advocacy Network and supported by independent educational grants from AstraZeneca and Genentech.

To complete the other activities in this series please click here

Target Audience

Urology community physicians, nurse practitioners, nurses, and pharmacists. 

Learning Objectives

  • Review conventional therapies for mUBC currently employed in community urology practice.
  • Explore FDA-approved immune checkpoint inhibitors (ICIs) used in mUBC regarding mechanism of action, dosing, and applications for use.

Additional Information

PDF icon Handout794.21 KB
Course summary
Available credit: 
  • 1.00 AAPA Category I CME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
Course expires: 

 Neal Shore, MD, FACS (Activity Chair)
 Director, CPI, Carolina Urologic Research Center
 Atlantic Urology Clinics
 Myrtle Beach, South Carolina


 Noah M. Hahn, MD
 Associate Professor of Medicine
 Department of Oncology and Urology
 Johns Hopkins University School of Medicine
 Baltimore, Maryland


Ashish M. Kamat, MD, MBBS, FACS
Professor, Department of Urology
Division of Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Susan H. Gitzinger, PharmD, MPA–has no financial relationships to disclose in relation to this activity. 
Kirollos S. Hanna, PharmD, BCPS, BCOP–has disclosed that he is a consultant for Seattle Genetics and is a member of the speakers' bureau for Astellas, Bristol-Myers Squibb, and Seattle Genetics. 

Neal Shore, MD, FACS–has disclosed that he is a consultant and receives grant/research support from Abbvie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Color Genomics, Dendreon, Ferring, Genentech, Genomic Health, Genzyme, Innovia, Invitae, Janssen, Merck, Myriad, Nymox, Panacea, Pfizer, Roche, Sanofi, and Tolmar.

Noah M. Hahn, MD–has disclosed that he is a consultant for Genentech, Ciclomed, Incyte, Janssen, Merck, and Seattle Genetics. His institution receives grant/research support from AstraZeneca,  Bristol-Myers Squibb, Incyte, Inovio, Pieris, Principia, and Merck. 

Ashish M. Kamat, MD, MBBS, FACS–has disclosed that he is a consultant for Arquer, Asieris, AstraZeneca, BioClin Therapeutics, BMS, Cepheid, Cold Genesys, Eisai, Ferring, FKD IBCG, Imaging, MDxHealth, Medac, Merck, Pfizer, Photocure, Roviant, Sessen, Bio Theralase, TMC Innovation, and US Biotest. Receives grant/research support from AIBCCR, BMS, FKD Industries, Merck, Photocure, SWOG/NIH, and SPORE. 

Content Reviewers
Bishoy Morris Faltas, MD–has no financial relationships to disclose in relation to this activity. 
Sami Larson, PharmD–has no financial relationships to disclose in relation to this activity. 
Caroline Pratz, CRNP–has no financial relationships to disclose in relation to this activity. 

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-019-H01-P).

Nursing (ANCC)
This activity is designated for 1.0 contact hour.


Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® NABP® CPE Monitor electronic CE tracking system.

Available Credit

  • 1.00 AAPA Category I CME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.